Disruptive behaviour's treatment with paliperidone in autistic disorder: Review and case report

Autor:	M. García Moreno, B. Poza Cano, L. Beatobe Carreño, A. De Cos Milas
Rok vydání:	2016
Předmět:	medicine.medical_specialty Risperidone medicine.drug_class Social environment Atypical antipsychotic Irritability medicine.disease Psychiatry and Mental health Social skills medicine Autism Paliperidone medicine.symptom Adverse effect Psychology Psychiatry Clinical psychology medicine.drug
Zdroj:	European Psychiatry. 33:S631-S631
ISSN:	1778-3585 0924-9338
DOI:	10.1016/j.eurpsy.2016.01.2371
Popis:	IntroductionAutistic disorder (AD) is a neuropsychiatric disorder that often presents significant disruptive symptoms such as irritability, aggression and self-injury in addition to impairment of social skills and communication. These symptoms interfere both individuals with AD and their families and social environment.ObjectiveShow paliperidone effect in behavioural symptoms in AD.MethodsLiterature review about behavioural symptoms in AD and paliperidone effect in its treatment, followed by a case report of clinical improvement after treatment with paliperidone in a patient with autism. Agitation subscale Aberrant Behavior Checklist (ABC-I) scores was compared prior and 4 weeks after paliperidone treatment, and clinical improvement was assessed with Clinical Global Impression-Improvement Scale (CGI-I).ResultsAlthough risperidone has been one of the most studied atypical antipsychotic to treat this symptoms, its use should be limited in order to avoid extrapyramidal and metabolic symptoms. Paliperidone – the major metabolite of risperidone – has shown effectiveness in the treatment of behavioral symptoms in patients with autism, even in subjects with a prior ineffective trial of risperidone. Our patient, 21-years-old male with AD and significant disruptive symptoms was treated with paliperidone 9 mg/day. We observed a 20-points reduction in ABC-I scores 4 weeks later, with most significant improvement in items like auto-agression, heteroaggressivity, irritability and slams. CGI-I scores showed a much better improvement, and no significant adverse effects appeared.ConclusionsPaliperidone is an effective and safe treatment in behavioral symptoms associated to AD, with reduction in ABC-I subscale scores. More studies are needed to confirm our data.Disclosure of interestThe authors have not supplied their declaration of competing interest.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::670861a3de88f9c647b26dc6b4dbecf9 https://doi.org/10.1016/j.eurpsy.2016.01.2371 Zobrazit plný text záznamu